Importantly, our data is in agreement with the anti-atherogenic potential of sGC agonists and it is clear that the sGC enzyme plays a critical role in regulating several cell types and processes involved in atherogenesis and nephropathy, including vascular tone, fibrosis and inflammation, and that targeting this enzyme could prove beneficial for the overall health of the vascular endothelium and prevent renal disease progression. Here, SGCB is linked to kidney disorder.